For peptide cancer vaccines to be effective, they must contain both CD8+ and CD4+ epitopes to activate cytotoxic T lymphocytes (CTL) anti-tumor immunity and T helper cell activation to sustain the CTLs effector function (8). Here, CD4 is linked to neoplasm.